Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
-0.01 (-0.40%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.34 - 2.59
52 week 2.27 - 10.02
Open 2.59
Vol / Avg. 23,219.00/22,681.00
Mkt cap 10.90M
P/E     -
Div/yield     -
EPS -4.32
Shares 4.45M
Beta     -
Inst. own 8%
Jan 12, 2015
Biocept Inc at OneMedForum SF
Nov 13, 2014
Q3 2014 Biocept Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -37583.16% -6877.60%
Operating margin -36140.51% -5917.64%
EBITD margin - -5719.09%
Return on average assets -133.26% -659.65%
Return on average equity -302.72% -
Employees 27 -
CDP Score - -


Suite 150, 5810 Nancy Ridge Drive
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biocept, Inc.(Biocept) is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC), and circulating tumor Deoxyribonucleic acid (DNA), (ctDNA), tests utilizing a standard blood sample. These tests (including its OncoCEE-BRTM breast cancer CTC test, which is already on the market) are designed to provide information to oncologists to enable them to select appropriate treatment. Cell Enrichment and Extraction (CEE) is an internally invented and developed, microfluidics-based CTC capture and analysis platform. Circulating tumor cells are cancer cells that have detached from the tumor matrix and invaded the patient�s blood or other bodily fluids. OncoCEE CTC tests for cancer types other than breast cancer, with a focus on population solid tumor types, or cancers for which there are approved therapies that rely on biomarker tests.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
William G. Kachioff Chief Financial Officer, Senior Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Bruce A. Huebner Independent Director
Age: 63
Bio & Compensation  - Reuters
Edward A. Neff Independent Director
Age: 63
Bio & Compensation  - Reuters